
13.47 Delayed Data As of Jun 29 | ![]() Today’s Change | 6.51 Today|||52-Week Range 37.99 | +37.87% Year-to-Date |
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry Jun 17 / Zacks.com - Paid Partner Content |
Previous close | 13.35 |
Today’s open | 13.01 |
Day’s range | 13.01 - 13.53 |
Volume | 596,736 |
Average volume (3 months) | 1,266,326 |
Market cap | $911.1M |
Earnings growth (last year) | -8.10% |
Earnings growth (this year) | +48.45% |
Earnings growth (next 5 years) | +21.00% |
Revenue growth (last year) | +128.45% |
P/E ratio | NM |
Price/Sales | 5.90 |
Price/Book | 2.64 |
Today’s change | Today’s % change | |
---|---|---|
QUREUniqure NV | -0.10 | -0.54% |
EDITEditas Medicine Inc | -0.22 | -1.77% |
RCKTRocket Pharmaceutica... | +0.16 | +1.24% |
REPLReplimune Group Inc | +0.29 | +1.69% |
Next reporting date | August 9, 2022 |
EPS forecast (this quarter) | -$0.66 |
Annual revenue (last year) | $96.1M |
Annual profit (last year) | -$300.0M |
Net profit margin | -311.98% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |